FATE THERAPEUTICS INC Increase (Decrease) in Contract with Customer, Liability
FATE THERAPEUTICS INC (FATE) reported Increase (Decrease) in Contract with Customer, Liability of -$382.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-13
- FATE THERAPEUTICS INC increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$582.00K.
- FATE THERAPEUTICS INC increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $200.00K.
- FATE THERAPEUTICS INC increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $377.00K.
- FATE THERAPEUTICS INC increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $4.00K.
- FATE THERAPEUTICS INC increase (decrease) in contract with customer, liability for fiscal 2025 was -$12.00K.
- FATE THERAPEUTICS INC increase (decrease) in contract with customer, liability for fiscal 2024 was -$892.00K.
- FATE THERAPEUTICS INC increase (decrease) in contract with customer, liability for fiscal 2023 was -$41.54M.
- FATE THERAPEUTICS INC increase (decrease) in contract with customer, liability for fiscal 2022 was -$6.38M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$582.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$382.00K 10-Q · filed 2026-08-13 | -$5.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-13 | $577.00K derived: sum of 2 quarters · filed 2026-05-13 | $581.00K derived: sum of 3 quarters · filed 2026-05-13 | $369.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $381.00K derived: sum of 2 quarters · filed 2026-02-26 | $169.00K derived: sum of 3 quarters · filed 2026-08-13 | -$12.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$208.00K derived: sum of 2 quarters · filed 2026-08-13 | -$389.00K 10-Q · filed 2025-11-13 | -$596.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$212.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$393.00K 10-Q · filed 2026-08-13 | -$600.00K derived: sum of 3 quarters · filed 2026-08-13 | -$600.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$181.00K 10-Q · filed 2026-05-13 | -$388.00K derived: sum of 2 quarters · filed 2026-05-13 | -$388.00K derived: sum of 3 quarters · filed 2026-05-13 | -$548.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$207.00K derived: sum of 2 quarters · filed 2026-02-26 | -$367.00K derived: sum of 3 quarters · filed 2026-02-26 | -$892.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$160.00K derived: sum of 2 quarters · filed 2025-11-13 | -$685.00K 10-Q · filed 2025-11-13 | -$1.11M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$685.00K 10-Q · filed 2025-08-12 | -$1.11M derived: sum of 3 quarters · filed 2025-08-12 | -$1.93M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$525.00K 10-Q · filed 2025-05-13 | -$950.00K derived: sum of 2 quarters · filed 2025-05-13 | -$1.77M derived: sum of 3 quarters · filed 2025-05-13 | -$1.58M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$425.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$1.25M derived: sum of 2 quarters · filed 2025-03-05 | -$1.05M derived: sum of 3 quarters · filed 2025-03-05 | -$41.54M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$820.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$628.00K derived: sum of 2 quarters · filed 2024-11-12 | -$41.12M 10-Q · filed 2024-11-12 | -$46.54M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$40.30M 10-Q · filed 2024-08-13 | -$45.72M derived: sum of 3 quarters · filed 2024-08-13 | -$49.47M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$40.49M 10-Q · filed 2024-05-09 | -$45.91M derived: sum of 2 quarters · filed 2024-05-09 | -$49.66M derived: sum of 3 quarters · filed 2024-05-09 | -$43.37M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$9.17M derived: sum of 2 quarters · filed 2024-02-26 | -$2.88M derived: sum of 3 quarters · filed 2024-02-26 | -$6.38M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.54M derived: sum of 2 quarters · filed 2023-11-08 | -$959.00K 10-Q · filed 2023-11-08 | -$8.46M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $6.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.79M 10-Q · filed 2023-08-08 | -$4.71M derived: sum of 3 quarters · filed 2023-08-08 | -$10.56M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$3.50M 10-Q · filed 2023-05-03 | -$11.00M derived: sum of 2 quarters · filed 2023-05-03 | -$16.85M derived: sum of 3 quarters · filed 2023-05-03 | -$18.95M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | -$7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$13.35M derived: sum of 2 quarters · filed 2023-02-28 | -$15.45M derived: sum of 3 quarters · filed 2023-02-28 | -$18.56M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$5.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$7.95M derived: sum of 2 quarters · filed 2022-11-03 | -$11.06M 10-Q · filed 2022-11-03 | -$10.39M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$5.21M 10-Q · filed 2022-08-03 | -$4.54M derived: sum of 3 quarters · filed 2023-02-28 | -$7.36M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$3.11M 10-Q · filed 2022-05-04 | -$2.44M derived: sum of 2 quarters · filed 2023-02-28 | -$5.26M derived: sum of 3 quarters · filed 2023-02-28 | $58.01M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $666.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$2.15M derived: sum of 2 quarters · filed 2023-02-28 | $61.12M derived: sum of 3 quarters · filed 2023-02-28 | $60.60M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $60.45M derived: sum of 2 quarters · filed 2021-11-04 | $59.94M 10-Q · filed 2021-11-04 | $58.64M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $63.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $62.75M 10-Q · filed 2021-08-04 | $61.45M derived: sum of 3 quarters · filed 2022-02-28 | $59.02M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$515.00K 10-Q · filed 2021-05-05 | -$1.82M derived: sum of 2 quarters · filed 2022-02-28 | -$4.25M derived: sum of 3 quarters · filed 2022-02-28 | -$6.91M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$3.73M derived: sum of 2 quarters · filed 2022-02-28 | -$6.39M derived: sum of 3 quarters · filed 2022-02-28 | -$8.53M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$2.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$5.09M derived: sum of 2 quarters · filed 2020-11-05 | -$7.22M 10-Q · filed 2020-11-05 | -$3.39M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$4.79M 10-Q · filed 2020-08-05 | -$957.00K derived: sum of 3 quarters · filed 2021-02-24 | $8.52M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$2.13M 10-Q · filed 2020-05-11 | $1.71M derived: sum of 2 quarters · filed 2021-02-24 | $11.18M derived: sum of 3 quarters · filed 2021-02-24 | $10.65M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $13.31M derived: sum of 2 quarters · filed 2021-02-24 | $12.79M derived: sum of 3 quarters · filed 2021-02-24 | $12.26M 10-K · filed 2021-02-24 |
| 2018-09-30 | $9.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $8.95M derived: sum of 2 quarters · filed 2019-11-05 | $8.42M 10-Q · filed 2019-11-05 | $7.89M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$527.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$1.05M 10-Q · filed 2019-08-06 | -$1.58M derived: sum of 3 quarters · filed 2020-03-02 | -$2.10M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$526.00K 10-Q · filed 2019-05-07 | -$1.05M derived: sum of 2 quarters · filed 2020-03-02 | -$1.58M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$526.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$1.05M derived: sum of 2 quarters · filed 2020-03-02 | -$2.10M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$526.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$1.58M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | -$1.05M 10-Q · filed 2018-08-06 | |||
| 2016-12-31 | -$2.40M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |